Voruciclib (P1446A), a CDK1/2/4/5/6/8/9 inhibitor, was evaluated in a phase I study recruiting follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, CLL, diffuse large B-cell lymphoma, and AML patients after demonstrating significant potential in preclinical studies [61,107]. This evidence concerns the gene CDK1 and mantle cell lymphoma.